CSPC Pharmaceutical Group Ltd. has announced that its recombinant fully human anti-βKlotho monoclonal antibody drug, JMT202, has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. This drug, an FGFR1c/βKlotho receptor agonist, is designed to regulate glycolipid metabolism and has potential applications in treating metabolism-related diseases such as dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and obesity. The clinical trial will focus on hypertriglyceridemia $(HTG.UK)$. JMT202 has previously obtained approval from the National Medical Products Administration of China and is undergoing trials in China. Preclinical studies have shown that the drug has a favorable safety profile and can significantly reduce triglyceride levels, suggesting promising clinical development potential.